uploads/2018/06/bacteria-163711_1280.jpg

What Analysts Thought of Ligand Pharmaceuticals in June

By

Updated

Company overview

Ligand Pharmaceuticals (LGND) is engaged in developing and acquiring technologies for the development of medicines. The technologies the company employs include antibody discovery, nuclear receptor assays, high-throughput computer screening, and the formulation of science and liver-targeted prodrug techniques.

Ligand Pharmaceuticals currently has partnerships and licensing agreements with more than 95 healthcare companies and more than 165 programs under license in different commercializations and stages of development.

Article continues below advertisement

Analysts’ recommendations

Two of the six analysts covering Ligand Pharmaceuticals in June gave the stock “strong buy” ratings, and four gave it “buy” ratings. The mean rating for the stock was 1.67, and its target price was $204.6.

Peers’ ratings

In June, eight of the total nine analysts covering Repligen (RGEN) gave the stock “buy” or higher ratings, while one gave it a “hold” rating. The mean rating for the stock was 1.56, and its target price was $47.4.

Seven of the total eight analysts covering Acadia Pharmaceuticals (ACAD) gave the stock “buy” or higher ratings in June, while one gave it a “hold” rating. The mean rating for the stock was 2, and its target price was $47.29.

Of the 26 analysts covering Gilead Sciences (GILD) in June, 17 gave the stock “buy” or higher ratings, and nine gave it “hold” ratings. The mean rating for the stock was 2.12, and its target price was $85.77.

In the next article, we’ll take a look at the financial performance of Ligand Pharmaceuticals.

Advertisement

More From Market Realist